SCHEMBL3014474

SCHEMBL3014474

COc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(OC)c(OC)c4)CC3)n2)c(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.49
TSHR P16473 2/20 0.49
HTT P42858 2/20 0.49
HSD17B10 Q99714 3/20 0.49
MAPT P10636 3/20 0.49
USP2 O75604 2/20 0.49
RECQL P46063 1/20 0.49
GPBAR1 Q8TDU6 1/20 0.48
HDAC3 O15379 2/20 0.48
HDAC4 P56524 2/20 0.48
HDAC1 Q13547 2/20 0.48
HDAC7 Q8WUI4 2/20 0.48
HDAC2 Q92769 2/20 0.48
HDAC10 Q969S8 2/20 0.48
HDAC11 Q96DB2 2/20 0.48
HDAC8 Q9BY41 2/20 0.48
HDAC6 Q9UBN7 2/20 0.48
HDAC9 Q9UKV0 2/20 0.48
HDAC5 Q9UQL6 2/20 0.48
LMNA P02545 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008856 0.94 TSHR (0.50) POLBTSHRHTTHSD17B10MAPT
SCHEMBL3015477 0.91 MAPT (0.47) POLBTSHRHTTHSD17B10MAPT
SCHEMBL3012688 0.91 USP2 (0.51) POLBTSHRHSD17B10MAPTUSP2
SCHEMBL3012512 0.91 USP2 (0.51) POLBTSHRHSD17B10MAPTUSP2
SCHEMBL3018783 0.90 MAPT (0.61) POLBTSHRHTTHSD17B10MAPT
SCHEMBL3010727 0.90 MAPT (0.50) POLBTSHRHTTHSD17B10MAPT
SCHEMBL3651564 0.90 TP53 (0.46) POLBTSHRHTTHSD17B10MAPT
SCHEMBL3014595 0.89 ALDH1A1 (0.55) HTTHSD17B10MAPTUSP2RECQL
SCHEMBL3015038 0.89 HSD17B10 (0.57) POLBTSHRHTTHSD17B10MAPT
SCHEMBL3007248 0.89 POLB (0.51) POLBTSHRHTTHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA POLB 4649/4885TSHR 3320/4885HTT 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.